Franklin Street Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Franklin Street Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-60,000	Closed	-$538K	–	167
2025 Q2	$538K	Hold	60,000	–	–	0.03%	112
2025 Q1	$450K	Hold	60,000	–	–	0.03%	114
2024 Q4	$451K	Hold	60,000	–	–	0.03%	115
2024 Q3	$456K	Hold	60,000	–	–	0.03%	111
2024 Q2	$371K	Hold	60,000	–	–	0.03%	123
2024 Q1	$305K	Hold	60,000	–	–	0.02%	136
2023 Q4	$359K	Hold	60,000	–	–	0.03%	116
2023 Q3	$425K	Buy	60,000 +10,000	+20%	+$71.8K	0.04%	107
2023 Q2	$352K	Hold	50,000	–	–	0.03%	111
2023 Q1	$417K	Hold	50,000	–	–	0.04%	97
2022 Q4	$574K	Hold	50,000	–	–	0.05%	93
2022 Q3	$630K	Hold	50,000	–	–	0.06%	95
2022 Q2	$529K	Hold	50,000	–	–	0.05%	99
2022 Q1	$813K	Hold	50,000	–	–	0.07%	93
2021 Q4	$693K	Hold	50,000	–	–	0.05%	97
2021 Q3	$719K	Hold	50,000	–	–	0.06%	95
2021 Q2	$791K	Buy	+50,000	New	+$679K	0.07%	88
2021 Q1	–	Sell	-80,000	Closed	-$596K	–	150
2020 Q4	$596K	Buy	80,000 +5,000	+7%	+$25.8K	0.06%	98
2020 Q3	$258K	Hold	75,000	–	–	0.03%	124
2020 Q2	$357K	Hold	75,000	–	–	0.04%	110
2020 Q1	$150K	Buy	75,000 +25,000	+50%	+$68.8K	0.02%	128
2019 Q4	$173K	Sell	50,000 -14,000	-22%	-$35.2K	0.02%	147
2019 Q3	$183K	Buy	64,000 +50,000	+357%	+$156K	0.02%	150
2019 Q2	$53K	Sell	14,000 -50,000	-78%	-$301K	0.01%	155
2019 Q1	$521K	Buy	64,000 +20,000	+45%	+$171K	0.07%	105
2018 Q4	$355K	Buy	44,000 +1,000	+2%	+$7.78K	0.06%	108
2018 Q3	$328K	Hold	43,000	–	–	0.04%	124
2018 Q2	$246K	Sell	43,000 -6,000	-12%	-$33K	0.04%	136
2018 Q1	$234K	Hold	49,000	–	–	0.04%	140
2017 Q4	$241K	Hold	49,000	–	–	0.04%	145
2017 Q3	$257K	Hold	49,000	–	–	0.04%	126
2017 Q2	$272K	Hold	49,000	–	–	0.05%	121
2017 Q1	$412K	Hold	49,000	–	–	0.07%	116
2016 Q4	$310K	Hold	49,000	–	–	0.05%	145
2016 Q3	$216K	Sell	49,000 -20,000	-29%	-$79.9K	0.04%	167
2016 Q2	$196K	Hold	69,000	–	–	0.04%	182
2016 Q1	$195K	Hold	69,000	–	–	0.04%	205
2015 Q4	$712K	Hold	69,000	–	–	0.14%	127
2015 Q3	$787K	Hold	69,000	–	–	0.16%	122
2015 Q2	$1.03M	Hold	69,000	–	–	0.18%	116
2015 Q1	$623K	Sell	69,000 -30,000	-30%	-$311K	0.11%	130
2014 Q4	$1.2M	Buy	99,000 +6,000	+6%	+$66.3K	0.23%	99
2014 Q3	$910K	Hold	93,000	–	–	0.17%	117
2014 Q2	$1.19M	Hold	93,000	–	–	0.23%	107
2014 Q1	$984K	Sell	93,000 -46,000	-33%	-$490K	0.2%	114
2013 Q4	$1.06M	Hold	139,000	–	–	0.21%	109
2013 Q3	$1.01M	Hold	139,000	–	–	0.23%	110
2013 Q2	$216K	Buy	+139,000	New	+$240K	0.05%	224

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Street Advisors's BCRX Position: Q3 2025 in Review

Franklin Street Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2025, closing a stake of 60,000 shares — an estimated $538K sold.

Franklin Street Advisors first reported a position in BCRX in Q2 2013 and held it in 48 quarters. The position peaked at $1.2M in Q4 2014. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

Franklin Street Advisors reported no remaining BioCryst Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Franklin Street Advisors sold 60,000 BioCryst Pharmaceuticals shares in Q3 2025, an estimated $538K.
Franklin Street Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 48 quarters.
Franklin Street Advisors's BioCryst Pharmaceuticals position peaked at $1.2M in Q4 2014.
286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Franklin Street Advisors's 13F filing for Q3 2025, filed 9 Oct 2025.